To effectively suppressing allograft rejection in a recipient of an implant, further interdependently enhancing immunodepression effect and reduce a cyclosporin dose after an organ transplantation by using fructose diphosphate.

(A) A cyclosporin compound in an amount of an effective for suppressing a T-type lymphocyte activating response after organ transplantation operation and pharmaceutically permissible dose and (B) fructose-1,6-diphosphate in an amount of interdependently acting with the cyclosporin compound and thereby reducing a dose of the cyclosporin compound requiring for effectively suppressing a T-type lymphocyte activating response after an organ transplantation operation are administrated. Preferably, a method for administrating fructose-1,6-diphosphate to a patient by phleboclysis after the organ transplantation operation is exemplified as an administration method.